Ecancer shared on LinkedIn:
”Blinatumomab may offer a safer and more effective alternative to highly intensive chemotherapy for children with newly diagnosed high-risk B-cell acute lymphoblastic leukaemia (ALL).
In this ecancer interview from EHA2026, Martin Schrappe (University Hospital Schleswig-Holstein), discusses results from a randomised trial evaluating two cycles of blinatumomab as a replacement for conventional intensive chemotherapy blocks.
Key findings include:
- 4-year event-free survival of 83% with blinatumomab versus 70% with standard chemotherapy
- Lower relapse rates, including central nervous system relapse
- Substantially improved minimal residual disease responses
- Fewer severe toxicities, including reduced infections, mucositis and treatment-related mortality
- A modest increase in manageable neurological events
These results suggest that replacing highly intensive chemotherapy with blinatumomab can improve outcomes while reducing treatment-related toxicity.
The findings support a shift towards immunotherapy-based treatment strategies for children with high-risk B-ALL.
Watch the full interview with Martin Schrappe.”
You can also read ‘Uta Dirksen: Game-Changing Trial in Pediatric Acute Lymphoblastic Leukemia‘
